BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36975453)

  • 1. Health Care Costs Attributable to Prostate Cancer in British Columbia, Canada: A Population-Based Cohort Study.
    Zhang W; Guh DP; Mohammadi T; Pataky RE; Tam ACT; Lynd LD; Conklin AI
    Curr Oncol; 2023 Mar; 30(3):3176-3188. PubMed ID: 36975453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial health care costs for COVID-19 in British Columbia and Ontario, Canada: an interprovincial population-based cohort study.
    Tsui TCO; Zeitouny S; Bremner KE; Cheung DC; Mulder C; Croxford R; Del Giudice L; Lapointe-Shaw L; Mendlowitz A; Wong WWL; Perlis N; Sander B; Teckle P; Tomlinson G; Walker JD; Malikov K; McGrail KM; Peacock S; Kulkarni GS; Pataky RE; Krahn MD
    CMAJ Open; 2022; 10(3):E818-E830. PubMed ID: 36126976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare costs associated with prostate cancer: estimates from a population-based study.
    Krahn MD; Zagorski B; Laporte A; Alibhai SM; Bremner KE; Tomlinson G; Warde P; Naglie G
    BJU Int; 2010 Feb; 105(3):338-46. PubMed ID: 19594734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term health care costs for patients with prostate cancer: a population-wide longitudinal study in New South Wales, Australia.
    Cronin P; Kirkbride B; Bang A; Parkinson B; Smith D; Haywood P
    Asia Pac J Clin Oncol; 2017 Jun; 13(3):160-171. PubMed ID: 27619777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated Costs Associated With Radiation Therapy for Positive Surgical Margins During Radical Prostatectomy.
    Martini A; Marqueen KE; Falagario UG; Waingankar N; Wajswol E; Khan F; Fossati N; Briganti A; Montorsi F; Tewari AK; Stock R; Rastinehad AR
    JAMA Netw Open; 2020 Mar; 3(3):e201913. PubMed ID: 32232450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct Health Care Costs Associated With Multiple Sclerosis: A Population-Based Cohort Study in British Columbia, Canada, 2001-2020.
    Khakban A; Rodriguez Llorian E; Michaux KD; Patten SB; Traboulsee A; Oh J; Lynd LD;
    Neurology; 2023 Feb; 100(9):e899-e910. PubMed ID: 36450607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study.
    Stattin P; Sandin F; Thomsen FB; Garmo H; Robinson D; Lissbrant IF; Jonsson H; Bratt O
    Eur Urol; 2017 Jul; 72(1):125-134. PubMed ID: 27481175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
    Nair B; Wilt T; MacDonald R; Rutks I
    Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy.
    Sooriakumaran P; Nyberg T; Akre O; Widmark A; Hamdy F; Graefen M; Carlsson S; Steineck G; Wiklund NP
    Eur Urol; 2017 Sep; 72(3):345-351. PubMed ID: 28416350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
    Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
    JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating direct healthcare costs attributable to laboratory-confirmed Lyme disease in Ontario, Canada: A population-based matched cohort study using health administrative data.
    Shing E; Wang J; Khoo E; Evans GA; Moore S; Nelder MP; Patel SN; Russell C; Sider D; Sander B
    Zoonoses Public Health; 2019 Jun; 66(4):428-435. PubMed ID: 30665259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active treatment in low-risk prostate cancer: a population-based study.
    Roy S; Hyndman ME; Danielson B; Fairey A; Lee-Ying R; Cheung WY; Afzal AR; Xu Y; Abedin T; Quon HC
    Curr Oncol; 2019 Aug; 26(4):e535-e540. PubMed ID: 31548822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.
    Sanyal C; Aprikian AG; Cury FL; Chevalier S; Dragomir A
    Cancer; 2016 Apr; 122(7):1085-96. PubMed ID: 26828716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation.
    Seikkula H; Boström PJ; Seppä K; Pitkäniemi J; Malila N; Kaipia A
    BMC Urol; 2020 Mar; 20(1):25. PubMed ID: 32164671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
    Carrie C; Magné N; Burban-Provost P; Sargos P; Latorzeff I; Lagrange JL; Supiot S; Belkacemi Y; Peiffert D; Allouache N; Dubray BM; Servagi-Vernat S; Suchaud JP; Crehange G; Guerif S; Brihoum M; Barbier N; Graff-Cailleaud P; Ruffion A; Dussart S; Ferlay C; Chabaud S
    Lancet Oncol; 2019 Dec; 20(12):1740-1749. PubMed ID: 31629656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health care costs associated with hepatitis C: a longitudinal cohort study.
    Krajden M; Kuo M; Zagorski B; Alvarez M; Yu A; Krahn M
    Can J Gastroenterol; 2010 Dec; 24(12):717-26. PubMed ID: 21165379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct health-care costs attributed to hip fractures among seniors: a matched cohort study.
    Nikitovic M; Wodchis WP; Krahn MD; Cadarette SM
    Osteoporos Int; 2013 Feb; 24(2):659-69. PubMed ID: 22736067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.
    Pataky R; Gulati R; Etzioni R; Black P; Chi KN; Coldman AJ; Pickles T; Tyldesley S; Peacock S
    Int J Cancer; 2014 Aug; 135(4):939-47. PubMed ID: 24443367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare costs among men with favorable risk prostate cancer managed with observation strategies versus immediate treatment in an integrated healthcare system.
    Kariburyo F; Wang Y; Cheng IE; Wang L; Morgenstern D; Asner I; Xie L; Meadows E; Danella J
    J Med Econ; 2017 Aug; 20(8):825-831. PubMed ID: 28534659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.